Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
A comparative study of the renal glutaminase response to acidosis.
Acidosis
A lack of correlation between rat kidney mitochondrial swelling and glutaminase activation in metabolic acidosis.
Acidosis
Acid-base balance may influence risk for insulin resistance syndrome by modulating cortisol output.
Acidosis
Acidosis activation of the pituitary-adrenal-renal glutaminase I axis.
Acidosis
Adaptation of renal tricarboxylic acid cycle metabolism to various acid-base states: study with [3-13C,5-15N]glutamine.
Acidosis
Ammonia formation from glutamine isomers by nonacidotic and acidotic perfused rat kidneys.
Acidosis
Ammoniagenesis by cultured human renal cortical epithelial cells: study with 15N.
Acidosis
Biochemical and histocytochemical studies on response of ammonia-producing enzymes for nh4cl-induced acidosis.
Acidosis
Changes in the levels of translatable glutaminase mRNA during onset and recovery from metabolic acidosis.
Acidosis
Complexity and species variation of the kidney-type glutaminase gene.
Acidosis
Effect of acidosis on phosphoenolpyruvate carboxykinase and glutaminase mRNAs in rat kidney and in LLC-PK-F+ cells.
Acidosis
Effect of acidosis on the properties of the glutaminase mRNA pH-response element binding protein.
Acidosis
Effect of acute alterations in acid-base balance on rat renal glutaminase and phosphoenolpyruvate carboxykinase gene expression.
Acidosis
Effect of ischaemia and acidosis on glutaminase activity in the rat kidney.
Acidosis
Effect of pH on ammonia production by renal mitochondria.
Acidosis
Effects of age on renal function and enzyme activity in male C57BL/6 mice.
Acidosis
Glutamine metabolism in metabolic acidosis.
Acidosis
Hepatic enzymes of glutamine and ureagenesis in metabolic acidosis.
Acidosis
Hepatic glutaminase flux regulation of glutamine homeostasis. Studies in vivo.
Acidosis
Hormonal regulation of glutamine metabolism by OK cells.
Acidosis
Impact of Acidosis-Regulated MicroRNAs on the Expression of Their Target Genes in Experimental Tumors In Vivo.
Acidosis
Influence of acute metabolic acidosis on the monomer and polymer forms of renal phosphate-dependent glutaminase.
Acidosis
Interorgan glutamine flow in metabolic acidosis.
Acidosis
Mechanism of altered renal glutaminase gene expression in response to chronic acidosis.
Acidosis
Pathways of acute pH regulation of ammoniagenesis in LLC-PK1 cells: study with [15N]glutamine.
Acidosis
Perturbations in nitrogen metabolism of brain and liver of rat following repeated benthiocarb administration.
Acidosis
pH-responsive stabilization of glutamate dehydrogenase mRNA in LLC-PK1-F+ cells.
Acidosis
pH-responsive, gluconeogenic renal epithelial LLC-PK1-FBPase+cells: a versatile in vitro model to study renal proximal tubule metabolism and function.
Acidosis
Phosphate activation of glutaminase in sonicated mitochondria of normal and acidotic rat kidneys.
Acidosis
Phosphate-dependent glutaminase from rat kidney. Cause of increased activity in response to acidosis and identity with glutaminase from other tissues.
Acidosis
Phosphate-dependent glutaminase of rat skeletal muscle. Some properties and possible role in glutamine metabolism.
Acidosis
Phosphate-independent glutaminase from rat kidney. Partial purification and identity with gamma-glutamyltranspeptidase.
Acidosis
Properties of rat kidney glutaminase enzymes and their role in renal ammoniagenesis.
Acidosis
Regulation of flux through glutaminase and glutamine synthetase in isolated perfused rat liver.
Acidosis
Regulation of glutaminase activity and glutamine metabolism.
Acidosis
Regulation of interorganal glutamine flow in metabolic acidosis.
Acidosis
Regulation of renal glutaminase gene expression during metabolic acidosis.
Acidosis
Relationship of phosphate-dependent glutaminase activity to ammonia excretion in potassium deficiency and acidosis.
Acidosis
Renal ammoniagenesis and acid excretion in the dogfish, Squalus acanthias.
Acidosis
Renal ammonium production--une vue canadienne.
Acidosis
Renal enzymes during experimental diabetes mellitus in the rat. Role of insulin, carbohydrate metabolism, and ketoacidosis.
Acidosis
Renal metabolite concentrations and the activities of glutaminase and glutamate dehydrogenase during recovery from metabolic acidosis in the rat.
Acidosis
Renal phosphate-dependent glutaminase activity and ammonia excretion during acute acidosis in the rat.
Acidosis
Response of ammonia metabolism to acute acidosis: insights from cultured renal epithelium.
Acidosis
Response of LLC-PK1-F+ cells to metabolic acidosis.
Acidosis
Role of deadenylation and AUF1 binding in the pH-responsive stabilization of glutaminase mRNA.
Acidosis
The effect of metabolic acidosis on the synthesis and turnover of rat renal phosphate-dependent glutaminase.
Acidosis
The kidney of chicken adapts to chronic metabolic acidosis: in vivo and in vitro studies.
Acidosis
The maximal activity of phosphate-dependent glutaminase and glutamine metabolism in the colon and the small intestine of streptozotocin-diabetic rats.
Acidosis
The regulation of phosphate-activated glutaminase activity and glutamine metabolism in the streptozotocin-diabetic rat.
Acidosis
The role of pH and the lack of a requirement for hydorgencarbonate in the regulation of hepatic glutamine metabolism.
Acidosis
The SIRT1/HIF2? axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy.
Acidosis
Variations in the kinetic response of several different phosphate-dependent glutaminase isozymes during acute metabolic acidosis.
Acidosis
Zeta-crystallin mediates the acid pH-induced increase of BSC1 cotransporter mRNA stability.
Acidosis
[Activity of renal enzymes producing ammonia from glutamine in the absence of phosphate in the rat: 1. Effect of chronic metabolic acidosis]
Acidosis
[Nephrogenic metabolic acidosis]
Acidosis, Respiratory
The role of pH and the lack of a requirement for hydorgencarbonate in the regulation of hepatic glutamine metabolism.
Acute Kidney Injury
[Activity of glutamine deaminating enzymes in the kidneys, liver and serum of dogs with renal failure and under normal conditions]
Adenocarcinoma
Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters.
Adenocarcinoma
SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells.
Adenocarcinoma
Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.
Adenocarcinoma of Lung
Dual targeting of EGFR and glutaminase in lung cancer.
Adenocarcinoma of Lung
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.
Adenoma
Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas.
AIDS Dementia Complex
Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders.
AIDS Dementia Complex
STAT1 Regulates Human Glutaminase 1 Promoter Activity through Multiple Binding Sites in HIV-1 Infected Macrophages.
Alkalosis
Metabolic alkalosis as driving force for urea synthesis in liver disease: pathogenetic model and therapeutic implications.
Alkalosis
Regulation of flux through glutaminase and glutamine synthetase in isolated perfused rat liver.
Alkalosis
The maximal activity of phosphate-dependent glutaminase and glutamine metabolism in the colon and the small intestine of streptozotocin-diabetic rats.
Alkalosis
The regulation of phosphate-activated glutaminase activity and glutamine metabolism in the streptozotocin-diabetic rat.
Alzheimer Disease
APC/Cdh E3 ubiquitin ligase in the pathophysiology of Alzheimer?s disease.
Alzheimer Disease
Cortical glutaminase, beta-glucuronidase and glucose utilization in Alzheimer's disease.
Alzheimer Disease
Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.
Alzheimer Disease
Excitatory amino acids and Alzheimer's disease: idle thoughts on an exciting subject.
Alzheimer Disease
Glutamate and GABA-Metabolizing Enzymes in Post-mortem Cerebellum in Alzheimer's Disease: Phosphate-Activated Glutaminase and Glutamic Acid Decarboxylase.
Alzheimer Disease
Glutamate metabolizing enzymes in prefrontal cortex of Alzheimer's disease patients.
Alzheimer Disease
Glutaminase 1 Regulates Neuroinflammation After Cerebral Ischemia Through Enhancing Microglial Activation and Pro-Inflammatory Exosome Release.
Alzheimer Disease
Glutaminase C Regulates Microglial Activation and Pro-inflammatory Exosome Release: Relevance to the Pathogenesis of Alzheimer's Disease.
Alzheimer Disease
Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.
Alzheimer Disease
Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration.
Alzheimer Disease
Topographical distribution of neurochemical changes in Alzheimer's disease.
Alzheimer Disease
[Glutaminase in the cerebellum of patients with Alzheimer's disease: a postmortem brain study].
Alzheimer Disease
[Impaired cerebral glutamate metabolism in mental diseases (Alzheimer's disease, schizophrenia]
Amyotrophic Lateral Sclerosis
Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration.
Anemia
[Glutaminase activity in rabbit reticulocytes: determination and behavior during a blood-loss anemia]
Anemia, Hemolytic, Autoimmune
Anti tissue transglutaminase antibody in idiopathic autoimmune haemolytic anemia.
Arthritis, Rheumatoid
Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
Asthma
Airway nitric oxide release is reduced after PBS inhalation in asthma.
Astrocytoma
Glutaminolysis dynamics during astrocytoma progression correlates with tumor aggressiveness.
Ataxia
Extracellular Vesicles from Hyperammonemic Rats Induce Neuroinflammation and Motor Incoordination in Control Rats.
Ataxia Telangiectasia
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Brain Diseases
GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay.
Brain Diseases
Identification of a Loss-of-Function Mutation in the Context of Glutaminase Deficiency and Neonatal Epileptic Encephalopathy.
Brain Diseases
Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration.
Brain Diseases
THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy.
Brain Ischemia
Characterization of mitochondrial glutaminase and amino acids at prolonged times after experimental focal cerebral ischemia.
Brain Ischemia
Glutaminase 1 Regulates Neuroinflammation After Cerebral Ischemia Through Enhancing Microglial Activation and Pro-Inflammatory Exosome Release.
Brain Neoplasms
Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway.
Brain Neoplasms
Glutaminases in brain: Multiple isoforms for many purposes.
Breast Neoplasms
Antisense glutaminase inhibition modifies the O-GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells.
Breast Neoplasms
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer.
Breast Neoplasms
Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing.
Breast Neoplasms
Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase.
Breast Neoplasms
Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Breast Neoplasms
Design and evaluation of novel glutaminase inhibitors.
Breast Neoplasms
Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
Breast Neoplasms
ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation.
Breast Neoplasms
Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer.
Breast Neoplasms
Expression of recombinant human L-glutaminase in Escherichia coli: polyclonal antibodies production and immunological analysis of mouse tissues.
Breast Neoplasms
Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.
Breast Neoplasms
Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas.
Breast Neoplasms
Glutamine affects glutathione recycling enzymes in a DMBA-induced breast cancer model.
Breast Neoplasms
Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells.
Breast Neoplasms
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Breast Neoplasms
In Situ Metabolic Characterisation of Breast Cancer and Its Potential Impact on Therapy.
Breast Neoplasms
Kinetic Modeling of 18F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism.
Breast Neoplasms
Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Breast Neoplasms
Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype.
Breast Neoplasms
Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase.
Breast Neoplasms
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
Breast Neoplasms
N-terminal phosphorylation of glutaminase C decreases its enzymatic activity and cancer cell migration.
Breast Neoplasms
Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Breast Neoplasms
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.
Breast Neoplasms
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.
Breast Neoplasms
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.
Breast Neoplasms
The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.
Breast Neoplasms
The role of glutaminase in cancer.
Breast Neoplasms
Vitamin D regulation of HAS2, hyaluronan synthesis and metabolism in triple negative breast cancer cells.
Carcinogenesis
Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Carcinogenesis
Head and Neck Squamous Cell Carcinoma Metabolism Draws on Glutaminolysis, and Stemness Is Specifically Regulated by Glutaminolysis via Aldehyde Dehydrogenase.
Carcinogenesis
Identifying strategies to target the metabolic flexibility of tumours.
Carcinogenesis
Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Carcinogenesis
Metabolic fingerprinting reveals extensive consequences of GLS hyperactivity.
Carcinogenesis
Molecular modeling and LC-MS-based metabolomics of a glutamine-valproic acid (Gln-VPA) derivative on HeLa cells.
Carcinogenesis
Phosphorylation of glutaminase by PKC? is essential for its enzymatic activity and critically contributes to tumorigenesis.
Carcinogenesis
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.
Carcinogenesis
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.
Carcinogenesis
Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway.
Carcinoma
Amino acid metabolism in tumour-bearing mice.
Carcinoma
Breaking the ritual metabolic cycle in order to save acetyl CoA: A potential role for mitochondrial humanin in T2 bladder cancer aggressiveness.
Carcinoma
Early differential expression of two glutaminase mRNAs in mouse spleen after tumor implantation.
Carcinoma
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase.
Carcinoma
Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma.
Carcinoma
Glutaminase induced prolonged regression of established Ehrlich carcinoma.
Carcinoma
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Carcinoma
Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas.
Carcinoma
Localization of phosphate dependent glutaminase in ascites fluid of ovarian cancer patient.
Carcinoma
Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase.
Carcinoma
Phosphate-activated glutaminase expression during tumor development.
Carcinoma
Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.
Carcinoma
Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential.
Carcinoma
The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy.
Carcinoma
[Action of swine kidney L-glutaminase on Ehrlich carcinoma]
Carcinoma
[Concentration of free glutamine and glutaminase activity in the gastric mucosa of patients with precancerous diseases and cancer of the stomach]
Carcinoma, Ductal
The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.
Carcinoma, Ehrlich Tumor
Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells.
Carcinoma, Ehrlich Tumor
Changes in mRNAs for enzymes of glutamine metabolism in the tumor-bearing mouse.
Carcinoma, Ehrlich Tumor
Ehrlich ascites tumor cells expressing anti-sense glutaminase mRNA lose their capacity to evade the mouse immune system.
Carcinoma, Ehrlich Tumor
Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display.
Carcinoma, Ehrlich Tumor
Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells.
Carcinoma, Ehrlich Tumor
Properties and intracellular localization of Ehrlich ascites tumor cell glutaminase.
Carcinoma, Ehrlich Tumor
Sensitisation of Ehrlich ascitic tumour cells to methotrexate by inhibiting glutaminase.
Carcinoma, Embryonal
Autocrine glutamatergic transmission for the regulation of embryonal carcinoma stem cells.
Carcinoma, Hepatocellular
1C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine.
Carcinoma, Hepatocellular
Anomalous distribution of glutaminase isozyme in various hepatomas.
Carcinoma, Hepatocellular
Biochemical Characterization and Antitumor Study of L-Glutaminase from Bacillus cereus MTCC 1305.
Carcinoma, Hepatocellular
Biosynthesis and processing of mitochondrial glutaminase in HTC hepatoma cells.
Carcinoma, Hepatocellular
Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Glutaminase activities and growth rates of rat hepatomas.
Carcinoma, Hepatocellular
Glutaminase activity of glutamine-dependent carbamoyl-phosphate synthase from rat ascites hepatoma. Regulation by adenosine triphosphate-magensium and magnesium ion.
Carcinoma, Hepatocellular
Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma.
Carcinoma, Hepatocellular
Glutamine synthetase and glutaminase activities in various hepatoma cells.
Carcinoma, Hepatocellular
Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Modulation of cellular proliferation alters glutamine transport and metabolism in human hepatoma cells.
Carcinoma, Hepatocellular
Nuclear factor-?B p65 regulates glutaminase 1 expression in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Purification and characterization of l-glutaminase enzyme from camel liver: Enzymatic anticancer property.
Carcinoma, Hepatocellular
Rat hepatic glutaminase: identification of the full coding sequence and characterization of a functional promoter.
Carcinoma, Hepatocellular
Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Carcinoma, Hepatocellular
The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Carcinoma, Intraductal, Noninfiltrating
The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.
Carcinoma, Lewis Lung
Amino acid metabolism in tumour-bearing mice.
Carcinoma, Non-Small-Cell Lung
A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway.
Carcinoma, Non-Small-Cell Lung
Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC.
Carcinoma, Non-Small-Cell Lung
Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.
Carcinoma, Renal Cell
The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy.
Carcinoma, Squamous Cell
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Carcinoma, Squamous Cell
Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential.
Carcinosarcoma
[The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells]
Cardiovascular Diseases
Metabolic Intersection of Cancer and Cardiovascular Diseases: Opportunities for Cancer Therapy.
Cataract
GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay.
Celiac Disease
Small intestine glutaminase deficiency in celiac disease.
Central Nervous System Diseases
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.
Cholera
Evidence for glutamate, in addition to acetylcholine and GABA, neurotransmitter synthesis in basal forebrain neurons projecting to the entorhinal cortex.
Chondrosarcoma
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Colonic Neoplasms
A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells.
Colonic Neoplasms
A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
Colonic Neoplasms
Epigenetic silencing of glutaminase 2 in human liver and colon cancers.
Colonic Neoplasms
Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth.
Colorectal Neoplasms
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
Colorectal Neoplasms
Expression of glutaminase is upregulated in colorectal cancer and of clinical significance.
Colorectal Neoplasms
GLS1 depletion inhibited colorectal cancer proliferation and migration via redox/Nrf2/autophagy-dependent pathway.
Colorectal Neoplasms
Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization.
Colorectal Neoplasms
Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer.
Colorectal Neoplasms
Intratumoral heterogeneity of glutaminase and lactate dehydrogenase A protein expression in colorectal cancer.
Colorectal Neoplasms
L-Glutaminase Synthesis by Marine Halomonas meridiana Isolated from the Red Sea and Its Efficiency against Colorectal Cancer Cell Lines.
Coma
Acute metabolic effects of ammonia on the enzymes of glutamate metabolism in isolated astroglial cells.
Crohn Disease
Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation?
Crush Syndrome
[Enzymatic activity in the organism in experimental crush syndrome of the limbs. III. Arginase in kidney and liver, glutaminase in kidney.]
Dementia
Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.
Dementia
HIV-infected macrophages mediate neuronal apoptosis through mitochondrial glutaminase.
Dementia
Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?
Dementia
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.
Dementia
Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia.
Dementia
Potentiation of Excitotoxicity in HIV-1 Associated Dementia and the Significance of Glutaminase.
Dementia
Small molecule glutaminase inhibitors block glutamate release from stimulated microglia.
Diabetes Mellitus
Role of diabetes mellitus on hepatic encephalopathy.
Diabetes Mellitus, Experimental
[Glutamine synthetase and glutaminase activity in the brain and liver homogenates and subcellular fractions of rats with alloxan diabetes (3)]
Diabetes Mellitus, Type 2
Role of diabetes mellitus on hepatic encephalopathy.
Diabetic Ketoacidosis
Effect of diabetic ketosis on jejunal glutaminase.
Down Syndrome
Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.
Encephalitis
IL-1? and TNF-? induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase.
Encephalomyelitis
Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis
Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus-like Disease in MRL/lpr Mice and Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis, Autoimmune, Experimental
Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus-like Disease in MRL/lpr Mice and Experimental Autoimmune Encephalomyelitis.
Endometrial Hyperplasia
Autophagy in the physiological endometrium and cancer.
Endometrial Neoplasms
Autophagy in the physiological endometrium and cancer.
Endotoxemia
Activation of hepatic glutaminase in the endotoxin-treated rat.
Endotoxemia
Adaptive regulation in skeletal muscle glutamine metabolism in endotoxin-treated rats.
Eosinophilia
Targeting In Vivo Metabolic Vulnerabilities of Th2 and Th17 Cells Reduces Airway Inflammation.
Epilepsy
Increased expression of phosphate-activated glutaminase in hippocampal neurons in human mesial temporal lobe epilepsy.
Epilepsy
The anticonvulsant actions of carisbamate associate with alterations in astrocyte glutamine metabolism in the lithium-pilocarpine epilepsy model.
Epilepsy
The Glutamate-Glutamine Cycle in Epilepsy.
Epilepsy, Temporal Lobe
Increased expression of phosphate-activated glutaminase in hippocampal neurons in human mesial temporal lobe epilepsy.
Fatty Liver
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.
Fibrosarcoma
Adaptive alterations in cellular metabolism with malignant transformation.
Glioblastoma
A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity.
Glioblastoma
Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.
Glioblastoma
Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery.
Glioblastoma
Cassane diterpenoid derivative induces apoptosis in IDH1 mutant glioma cells through the inhibition of glutaminase in vitro and in vivo.
Glioblastoma
Erratum: Majewska, E. et al. Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway. Cancers 2019, 11, 115.
Glioblastoma
Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma.
Glioblastoma
Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.
Glioblastoma
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Glioblastoma
MicroRNA-153 regulates glutamine metabolism in glioblastoma through targeting glutaminase.
Glioblastoma
Opposing roles of glutaminase isoforms in determining glioblastoma cell phenotype.
Glioblastoma
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells.
Glioblastoma
Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA repair gene MGMT and sensitizes the cells to alkylating agents.
Glioblastoma
Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway.
Glioblastoma
Upregulation of glutaminase 2 and neutrophil cytosolic factor 2 is associated with the poor prognosis of glioblastoma.
Glioma
A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity.
Glioma
Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.
Glioma
Cassane diterpenoid derivative induces apoptosis in IDH1 mutant glioma cells through the inhibition of glutaminase in vitro and in vivo.
Glioma
Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.
Glioma
Glutamate/glutamine metabolism coupling between astrocytes and glioma cells: neuroprotection and inhibition of glioma growth.
Glioma
Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma.
Glioma
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Glioma
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Glioma
Lack of expression of the liver-type glutaminase (LGA) mRNA in human malignant gliomas.
Glioma
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition.
Glioma
SNAP25 Inhibits Glioma Progression by Regulating Synapse Plasticity via GLS-Mediated Glutaminolysis.
Glioma
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.
Glioma
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.
Glioma
Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA repair gene MGMT and sensitizes the cells to alkylating agents.
Glioma
Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells.
Gliosarcoma
Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line.
glutamate dehydrogenase deficiency
The natural history of hyperuricemia among asymptomatic relatives of patients with gout.
glutaminase deficiency
Genetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice.
glutaminase deficiency
Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS.
glutaminase deficiency
Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS. Reply.
glutaminase deficiency
Identification of a Loss-of-Function Mutation in the Context of Glutaminase Deficiency and Neonatal Epileptic Encephalopathy.
glutaminase deficiency
Molecular Imaging of mGluR5 Availability with [11C]ABP68 in Glutaminase Heterozygous Mice.
glutaminase deficiency
Small intestine glutaminase deficiency in celiac disease.
Gout
Glutaminase activity in the kidney in gout.
Graves Disease
Metabolism of glucose and glutamine in lymphocytes from Graves' hyperthyroid patients: influence of methimazole treatment.
Head and Neck Neoplasms
Head and Neck Squamous Cell Carcinoma Metabolism Draws on Glutaminolysis, and Stemness Is Specifically Regulated by Glutaminolysis via Aldehyde Dehydrogenase.
Hematologic Neoplasms
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia.
Hepatic Encephalopathy
A genetic variant in the promoter of phosphate-activated glutaminase is associated with hepatic encephalopathy.
Hepatic Encephalopathy
Gut ammonia production and its modulation.
Hepatic Encephalopathy
Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy.
Hepatic Encephalopathy
Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells.
Hepatic Encephalopathy
Metformin inhibits glutaminase activity and protects against hepatic encephalopathy.
Hepatic Encephalopathy
Pathophysiology of hepatic encephalopathy and future treatment options.
Hepatic Encephalopathy
Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis.
Hepatic Encephalopathy
Rat cerebral mitochondrial glutaminase activity is unaffected by moderate hyperammonemia in two models.
Hepatic Encephalopathy
Role of diabetes mellitus on hepatic encephalopathy.
Hepatic Encephalopathy
Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy.
Hepatic Encephalopathy
Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration.
Hepatic Encephalopathy
THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy.
Hepatic Encephalopathy
Validation study associating glutaminase promoter variations with hepatic encephalopathy in East Asian populations.
Hepatic Encephalopathy
Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study.
Hepatic Encephalopathy
[Activity of l-glutamine amidohydrolase in the rat brain in experimental hepatic encephalopathy]
Hepatic Encephalopathy
[Ammonia content and glutamine synthetase and glutaminase activity in the brain in experimental hepatic coma]
Hepatitis
Cloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coli.
Hepatitis
Structural and functional insights into Erwinia carotovora L-asparaginase.
Herpes Simplex
MYC-induced reprogramming of glutamine catabolism supports optimal virus replication.
Huntington Disease
Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases.
Huntington Disease
Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.
Huntington Disease
Phosphate-activated glutaminase in relation to Huntington's disease and agonal state.
Hyperglycemia
Publisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemia.
Hyperglycemia
Targeting hepatic glutaminase activity to ameliorate hyperglycemia.
Hyperhomocysteinemia
Maternal vitamin B6 deficient or supplemented diets on expression of genes related to GABAergic, serotonergic or glutamatergic pathways in hippocampus of rat dams and their offspring.
Hypersensitivity
Circumventing the side effects of L-asparaginase.
Hypertension, Pulmonary
Simultaneous Pharmacologic Inhibition of Yes-Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic-co-Glycolic) Acid-Encapsulated Microparticles Improves Pulmonary Hypertension.
Hyperthyroidism
Effect of hypo- and hyperthyroidism on the function and metabolism of macrophages in rats.
Hyperthyroidism
Effects of hyperthyroidism on glucose, glutamine and ketone-body metabolism in the gut of the rat.
Hypoglycemia
[Parameters of energy and nitrogen metabolism in rats under insulin-induced hypoglycemia]
Ichthyosis, Lamellar
Efficient in vitro transfection of human keratinocytes with an adenovirus-enhanced receptor-mediated system.
Ileitis
Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation?
Infections
Cerebral ammonia levels and enzyme changes during Plasmodium yoelii infection in mice.
Infections
Endotoxin stimulates lymphocyte glutaminase expression.
Infections
Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase.
Infections
Glutamate secretion and metabotropic glutamate receptor 1 expression during Kaposi's sarcoma-associated herpesvirus infection promotes cell proliferation.
Infections
Glutaminase-containing microvesicles from HIV-1-infected macrophages and immune-activated microglia induce neurotoxicity.
Infections
Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis.
Infections
Glutamine was required for snakehead fish vesiculovirus (SHVV) propagation via replenishing the tricarboxylic acid cycle.
Infections
In vitro glutaminase regulation and mechanisms of glutamate generation in HIV-1-infected macrophage.
Infections
Interferon-? regulates glutaminase 1 promoter through STAT1 phosphorylation: relevance to HIV-1 associated neurocognitive disorders.
Infections
Mitochondrial Glutaminase Release Contributes to Glutamate-Mediated Neurotoxicity during Human Immunodeficiency Virus-1 Infection.
Infections
Proteomics and functional analyses of Arabidopsis nitrilases involved in the defense response to microbial pathogens.
Infections
[Influence of recombinant growth hormone on protein metabolism during severe infection: an animal experiment]
Influenza, Human
MYC-induced reprogramming of glutamine catabolism supports optimal virus replication.
Insulin Resistance
Clinical science workshop: targeting the gut-liver-brain axis.
Ketosis
Renal enzymes during experimental diabetes mellitus in the rat. Role of insulin, carbohydrate metabolism, and ketoacidosis.
Kidney Neoplasms
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Leukemia
A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
Leukemia
Biochemical characterization of a novel L-Asparaginase with low glutaminase activity from Rhizomucor miehei and its application in food safety and leukemia treatment.
Leukemia
Cloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coli.
Leukemia
Effect of cold atmospheric plasma treatment on the metabolites of human leukemia cells.
Leukemia
Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.
Leukemia
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Leukemia
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Leukemia
l-Asparaginase from Aspergillus spp.: production based on kinetics, thermal stability and biochemical characterization.
Leukemia
L-glutaminase activity in lymphocytes of patients with chronic lymphatic leukemia.
Leukemia
Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties.
Leukemia
Purification and characterization of glutaminase free asparaginase from Pseudomonas otitidis: Induce apoptosis in human leukemia MOLT-4 cells.
Leukemia
Structural and functional insights into Erwinia carotovora L-asparaginase.
Leukemia
Tumoricidal potential of nutritional manipulations.
Leukemia
[Cloning, expression and purification of Helicobater pylori L-asparaginase]
Leukemia, Erythroblastic, Acute
Prominent glutamine oxidation activity in mitochondria of hematopoietic tumors.
Leukemia, Lymphocytic, Chronic, B-Cell
L-glutaminase activity in lymphocytes of patients with chronic lymphatic leukemia.
Leukemia, Myeloid
Purification and Characterization of Glutaminase Free Asparaginase from Enterobacter cloacae: In-Vitro Evaluation of Cytotoxic Potential against Human Myeloid Leukemia HL-60 Cells.
Leukemia, Myeloid, Acute
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Leukemia, Myeloid, Acute
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Leukemia, Myeloid, Acute
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Liver Cirrhosis
Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Activation of Hepatic Stellate Cells.
Liver Cirrhosis
Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy.
Liver Cirrhosis
New technologies - new insights into the pathogenesis of hepatic encephalopathy.
Liver Cirrhosis
The role of WNT/?-catenin signaling pathway and glutamine metabolism in the pathogenesis of CCl4-induced liver fibrosis: Repositioning of niclosamide and concerns about lithium.
Liver Cirrhosis
Validation study associating glutaminase promoter variations with hepatic encephalopathy in East Asian populations.
Liver Cirrhosis
[Enzymes participating in the formation of ammonia in various experimental liver diseases]
Liver Failure
Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.
Liver Neoplasms
A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.
Liver Neoplasms
Circadian clock gene expression regulates cancer cell growth through glutaminase.
Lung Neoplasms
A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway.
Lung Neoplasms
An LC-MS Approach to Quantitative Measurement of Ammonia Isotopologues.
Lung Neoplasms
Dual targeting of EGFR and glutaminase in lung cancer.
Lung Neoplasms
Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC.
Lung Neoplasms
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation.
Lung Neoplasms
Inhibition of Anaplerotic Glutaminolysis Underlies Selenite Toxicity in Human Lung Cancer.
Lung Neoplasms
Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
Lung Neoplasms
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Lung Neoplasms
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition.
Lung Neoplasms
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.
Lung Neoplasms
Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition.
Lung Neoplasms
Phosphorylation of glutaminase by PKC? is essential for its enzymatic activity and critically contributes to tumorigenesis.
Lung Neoplasms
Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
Lymphatic Metastasis
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
Lymphoma
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.
Lymphoma, T-Cell
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase.
Malnutrition
Alterations in rat brain glutaminase and aldolase induced by lead ingestion following malnutrition.
Malnutrition
Effect of protein malnutrition on the glycolytic and glutaminolytic enzyme activity of rat thymus and mesenteric lymph nodes.
Melanoma
Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma.
Melanoma
Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
Melanoma
Human cutaneous melanoma expresses a significant phosphate-dependent glutaminase activity: a comparison with the surrounding skin of the same patient.
Melanoma
Long noncoding RNA OIP5-AS1 acts as a competing endogenous RNA to promote glutamine catabolism and malignant melanoma growth by sponging miR-217.
Melanoma
miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase.
Melanoma
Modulation of metastatic potential of B16F10 melanoma cells by acivicin: synergistic action of alutaminase and potentiation of cisplatin cytotoxicity.
Memory Disorders
Curcumin Requires Tumor Necrosis Factor ? Signaling to Alleviate Cognitive Impairment Elicited by Lipopolysaccharide.
Meningioma
Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.
Metabolic Diseases
Metabolic fingerprinting reveals extensive consequences of GLS hyperactivity.
Mouth Neoplasms
c-Myc Overexpression Promotes Oral Cancer Cell Proliferation and Migration by Enhancing Glutaminase and Glutamine Synthetase Activity.
Multiple Myeloma
Glutaminase inhibition in multiple myeloma induces apoptosis
Multiple Myeloma
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
Multiple Sclerosis
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.
Multiple Sclerosis
Small molecule glutaminase inhibitors block glutamate release from stimulated microglia.
Neoplasm Metastasis
Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.
Neoplasm Metastasis
Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells.
Neoplasm Metastasis
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
Neoplasm Metastasis
NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
Neoplasm Metastasis
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies.
Neoplasm Metastasis
Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.
Neoplasms
A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity.
Neoplasms
A Critical Role of Glutamine and Asparagine ?-Nitrogen in Nucleotide Biosynthesis in Cancer Cells Hijacked by an Oncogenic Virus.
Neoplasms
A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
Neoplasms
A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase.
Neoplasms
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.
Neoplasms
A Metabolomics Study of BPTES Altered Metabolism in Human Breast Cancer Cell Lines.
Neoplasms
A natural inhibitor of kidney-type glutaminase: a withanolide from
Neoplasms
A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway.
Neoplasms
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
Neoplasms
A series of transplantable rat mammary tumors with graded differentiation, growth rate, and glutaminase content.
Neoplasms
A Time for MYC: Metabolism and Therapy.
Neoplasms
Action at a distance: allostery and the development of drugs to target cancer cell metabolism.
Neoplasms
Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids.
Neoplasms
Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy.
Neoplasms
Amino acid metabolism in tumour-bearing mice.
Neoplasms
Angiogenesis a putative new approach in glutamine related therapy.
Neoplasms
Anti-tumor efficacy of glutaminase-copper-ATP combination in mice bearing Ehrlich ascites carcinoma.
Neoplasms
Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells.
Neoplasms
Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.
Neoplasms
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia.
Neoplasms
Author Correction: Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation.
Neoplasms
Autophagy in the physiological endometrium and cancer.
Neoplasms
Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy.
Neoplasms
Biomolecular Interaction Assays Identified Dual Inhibitors of Glutaminase and Glutamate Dehydrogenase That Disrupt Mitochondrial Function and Prevent Growth of Cancer Cells.
Neoplasms
Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.
Neoplasms
BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase.
Neoplasms
Breaking the ritual metabolic cycle in order to save acetyl CoA: A potential role for mitochondrial humanin in T2 bladder cancer aggressiveness.
Neoplasms
Breast cancer-derived extracellular vesicles stimulate myofibroblast differentiation and pro-angiogenic behavior of adipose stem cells.
Neoplasms
c-Myc Overexpression Promotes Oral Cancer Cell Proliferation and Migration by Enhancing Glutaminase and Glutamine Synthetase Activity.
Neoplasms
Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1?-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines.
Neoplasms
Cancer cell metabolism: implications for therapeutic targets.
Neoplasms
Caudatan A, an undescribed human kidney-type glutaminase inhibitor with tetracyclic flavan from Ohwia caudata.
Neoplasms
Changes in mRNAs for enzymes of glutamine metabolism in the tumor-bearing mouse.
Neoplasms
Changes in the glutaminase activity of liver tissue from rats during the development of hepatic tumors by carcinogen feeding.
Neoplasms
Characterisation and molecular dynamic simulations of J15 asparaginase from Photobacterium sp. strain J15.
Neoplasms
Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Neoplasms
Cholesterol inhibits glutamine metabolism in LLC WRC256 tumour cells but does not affect it in lymphocytes: possible implications for tumour cell proliferation.
Neoplasms
Circadian clock gene expression regulates cancer cell growth through glutaminase.
Neoplasms
Co-expression of glutaminase K and L isoenzymes in human tumour cells.
Neoplasms
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Neoplasms
Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase.
Neoplasms
Conformational Changes in the Activation Loop of Mitochondrial Glutaminase C: A Direct Fluorescence Read-Out that Distinguishes the Binding of Allosteric Inhibitors from Activators.
Neoplasms
Cytokines decrease glutaminase expression in human fibroblasts.
Neoplasms
Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting.
Neoplasms
Decrease of glutaminase expression by interferon-gamma in human intestinal epithelial cells.
Neoplasms
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Neoplasms
Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
Neoplasms
Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation.
Neoplasms
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
Neoplasms
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
Neoplasms
Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.
Neoplasms
Disruption of redox homeostasis for combinatorial drug efficacy in K-Ras tumors as revealed by metabolic connectivity profiling.
Neoplasms
Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
Neoplasms
Dual targeting of EGFR and glutaminase in lung cancer.
Neoplasms
Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types.
Neoplasms
Dysregulation of glutaminase and glutamine synthetase in cancer.
Neoplasms
Early differential expression of two glutaminase mRNAs in mouse spleen after tumor implantation.
Neoplasms
EFFECT OF ADMINISTRATION OF THE ENZYME GLUTAMINASE ON THE GROWTH OF CANCER CELLS.
Neoplasms
Effect of aging on the glutaminase activity of neoplastic and immune tissues.
Neoplasms
Effect of glutaminase inhibition on cancer-induced bone pain.
Neoplasms
Effect of He Plasma Jet Versus Surface Plasma on the Metabolites of Acute Myeloid Leukemia Cells.
Neoplasms
Effect of purified glutaminase from human ascites fluid on experimental tumor bearing mice.
Neoplasms
Effect of supplemental dietary glutamine on methotrexate concentrations in tumors.
Neoplasms
Effects of various dietary fatty acids on enzyme activities of carbohydrate and glutamine metabolism and the metabolic response of lymphocytes and macrophages during Walker-256 ascites cell tumour growth in rats.
Neoplasms
Ehrlich ascites tumor cells expressing anti-sense glutaminase mRNA lose their capacity to evade the mouse immune system.
Neoplasms
Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition.
Neoplasms
Erratum: Majewska, E. et al. Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway. Cancers 2019, 11, 115.
Neoplasms
Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters.
Neoplasms
Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors.
Neoplasms
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase.
Neoplasms
Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance.
Neoplasms
Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer.
Neoplasms
Expression of the glutamine metabolism-related proteins glutaminase 1 and glutamate dehydrogenase in canine mammary tumours.
Neoplasms
Expression, purification and crystallization of Helicobacter pylori L-asparaginase.
Neoplasms
GAC inhibitors with a 4-hydroxypiperidine spacer: Requirements for potency.
Neoplasms
GLS1 depletion inhibited colorectal cancer proliferation and migration via redox/Nrf2/autophagy-dependent pathway.
Neoplasms
GLS2 is protumorigenic in breast cancers.
Neoplasms
Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.
Neoplasms
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells.
Neoplasms
Glutamate released by Japanese encephalitis virus-infected microglia involves TNF-? signaling and contributes to neuronal death.
Neoplasms
Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.
Neoplasms
Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization.
Neoplasms
Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC.
Neoplasms
Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Neoplasms
Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells.
Neoplasms
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Neoplasms
Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma.
Neoplasms
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
Neoplasms
Glutaminase GLS1 Inhibitors as Potential Cancer Treatment.
Neoplasms
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation.
Neoplasms
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Neoplasms
Glutaminase Inhibitor CB-839 Increases Radiation Sensitivity of Lung Tumor Cells and Human Lung Tumor Xenografts in Mice.
Neoplasms
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Neoplasms
Glutaminase inhibitors: a patent review.
Neoplasms
Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress against Cancer.
Neoplasms
Glutaminase isoenzymes in the metabolic therapy of cancer.
Neoplasms
Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.
Neoplasms
Glutaminase regulation in cancer cells: a druggable chain of events.
Neoplasms
Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma.
Neoplasms
Glutaminase: a hot spot for regulation of cancer cell metabolism?
Neoplasms
Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas.
Neoplasms
Glutaminases in brain: Multiple isoforms for many purposes.
Neoplasms
Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
Neoplasms
Glutaminases regulate glutathione and oxidative stress in cancer.
Neoplasms
Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6.
Neoplasms
Glutamine affects glutathione recycling enzymes in a DMBA-induced breast cancer model.
Neoplasms
Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes.
Neoplasms
Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism.
Neoplasms
Glutamine facilitates chemotherapy while reducing toxicity.
Neoplasms
Glutamine homeostasis and mitochondrial dynamics.
Neoplasms
Glutamine in neoplastic cells: focus on the expression and roles of glutaminases.
Neoplasms
Glutamine Metabolism in Gliomas.
Neoplasms
Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Neoplasms
Glutamine Skipping the Q into Mitochondria.
Neoplasms
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Neoplasms
Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion.
Neoplasms
Glutamine-enriched diets support muscle glutamine metabolism without stimulating tumor growth.
Neoplasms
Glutaminolysis and carcinogenesis of oral squamous cell carcinoma.
Neoplasms
Glutaminolysis dynamics during astrocytoma progression correlates with tumor aggressiveness.
Neoplasms
Harry M. Vars Research Award. Glutamine enhances immunoregulation of tumor growth.
Neoplasms
Head and Neck Squamous Cell Carcinoma Metabolism Draws on Glutaminolysis, and Stemness Is Specifically Regulated by Glutaminolysis via Aldehyde Dehydrogenase.
Neoplasms
Hepatic glutaminase gene expression in the tumor-bearing rat.
Neoplasms
HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple-negative breast cancer.
Neoplasms
Identification of brain-specific angiogenesis inhibitor 2 as an interaction partner of glutaminase interacting protein.
Neoplasms
Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display.
Neoplasms
Identifying strategies to target the metabolic flexibility of tumours.
Neoplasms
Imaging tumour cell metabolism using hyperpolarized 13C magnetic resonance spectroscopy.
Neoplasms
Immunosuppressive Immature Myeloid Cell Generation Is Controlled by Glutamine Metabolism in Human Cancer.
Neoplasms
Impact of Acidosis-Regulated MicroRNAs on the Expression of Their Target Genes in Experimental Tumors In Vivo.
Neoplasms
Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma.
Neoplasms
Improvement in the persistence of microbial asparaginase and glutaminase in the circulation of the rat by chemical modifications.
Neoplasms
In Silico Analysis of Glutaminase from Different Species of Escherichia and Bacillus.
Neoplasms
In vivo and in vitro liver cancer metabolism observed with hyperpolarized [5-(13)C]glutamine.
Neoplasms
Influence of progressive tumor growth on glutamine metabolism in skeletal muscle and kidney.
Neoplasms
Influence of reduced concentration of L-glutamine on growth and viability of cells in monolayer, in spheroids, and in experimental tumours.
Neoplasms
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Neoplasms
Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer.
Neoplasms
Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth.
Neoplasms
Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells.
Neoplasms
Inhibition of glutaminase expression increases Sp1 phosphorylation and Sp1/Sp3 transcriptional activity in Ehrlich tumor cells.
Neoplasms
Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer.
Neoplasms
Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant cancers.
Neoplasms
Intratumoral heterogeneity of glutaminase and lactate dehydrogenase A protein expression in colorectal cancer.
Neoplasms
Investigation on glutamine amidohydrolase (EC 3.5.1.2) and glutamine aminotransferase (EC 2.5.1.15) activity in liver and plasma of EAC-bearing mice following glutaminase therapy.
Neoplasms
Investigation on phosphate dependent glutaminase (EC 3.5.1.2) activity in host tissues of EAC-bearing mice and response of liver EC 3.5.1.2 on Cu-ATP therapy.
Neoplasms
Involvement of essential cysteine and histidine residues in the activity of isolated glutaminase from tumour cells.
Neoplasms
Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate.
Neoplasms
Isolation and purification of phosphate dependent glutaminase from sarcoma-180 tumor and its antineoplastic effects on murine model system.
Neoplasms
Isolation and screening of extracellular anticancer enzymes from halophilic and halotolerant bacteria from different saline environments in Iran.
Neoplasms
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Neoplasms
Kidney-Type Glutaminase Inhibitor Hexylselen Selectively Kills Cancer Cells via a Three-Pronged Mechanism.
Neoplasms
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.
Neoplasms
Kinetic properties of Streptomyces canarius L- Glutaminase and its anticancer efficiency.
Neoplasms
L-Glutaminase Synthesis by Marine Halomonas meridiana Isolated from the Red Sea and Its Efficiency against Colorectal Cancer Cell Lines.
Neoplasms
Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Neoplasms
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.
Neoplasms
LncRNA EPB41L4A-AS1 regulates glycolysis and glutaminolysis by mediating nucleolar translocation of HDAC2.
Neoplasms
Mammalian glutaminase Gls2 gene encodes two functional alternative transcripts by a surrogate promoter usage mechanism.
Neoplasms
Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells.
Neoplasms
Mechanistic Basis of Glutaminase Activation: A Key Enzyme that Promotes Glutamine Metabolism in Cancer Cells.
Neoplasms
Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition.
Neoplasms
Metabolic and OXPHOS Activities Quantified by Temporal ex vivo Analysis Display Patient-Specific Metabolic Vulnerabilities in Human Breast Cancers.
Neoplasms
Metabolic Intersection of Cancer and Cardiovascular Diseases: Opportunities for Cancer Therapy.
Neoplasms
Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
Neoplasms
Metabolic reprogramming of cancer by chemicals that target glutaminase isoenzymes.
Neoplasms
Metabolic reprogramming sustains cancer cell survival following extracellular matrix detachment.
Neoplasms
Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells.
Neoplasms
miR-1-3p Contributes to Cell Proliferation and Invasion by Targeting Glutaminase in Bladder Cancer Cells.
Neoplasms
miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase.
Neoplasms
Mitochondrial glutathione depletion by glutamine in growing tumor cells.
Neoplasms
Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism.
Neoplasms
Modulation of metastatic potential of B16F10 melanoma cells by acivicin: synergistic action of alutaminase and potentiation of cisplatin cytotoxicity.
Neoplasms
Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase.
Neoplasms
Molecular modeling and LC-MS-based metabolomics of a glutamine-valproic acid (Gln-VPA) derivative on HeLa cells.
Neoplasms
Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Neoplasms
Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation.
Neoplasms
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer.
Neoplasms
MYC, microRNAs and glutamine addiction in cancers.
Neoplasms
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
Neoplasms
N-terminal phosphorylation of glutaminase C decreases its enzymatic activity and cancer cell migration.
Neoplasms
Neovascularisation offers a new perspective to glutamine related therapy.
Neoplasms
Novel 1,3,4-Selenadiazole Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
Neoplasms
Novel glutaminase free L-asparaginase from Nocardiopsis alba NIOT-VKMA08: production, optimization, functional and molecular characterization.
Neoplasms
NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism.
Neoplasms
Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation.
Neoplasms
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Neoplasms
p63 regulates glutaminase 2 expression.
Neoplasms
Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells.
Neoplasms
Patents targeting the Warburg effect for cancer therapy: an interview with William P Katt.
Neoplasms
PEG-PHB-glutaminase nanoparticle inhibits cancer cell proliferation in vitro through glutamine deprivation.
Neoplasms
Pharmacokinetic Assessment of 18F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer.
Neoplasms
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
Neoplasms
Phosphate-activated glutaminase expression during tumor development.
Neoplasms
Phosphorylation of glutaminase by PKC? is essential for its enzymatic activity and critically contributes to tumorigenesis.
Neoplasms
Physapubescin I from husk tomato suppresses SW1990 cancer cell growth by targeting kidney-type glutaminase.
Neoplasms
Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor.
Neoplasms
Probing the structure and function of human glutaminase-interacting protein: a possible target for drug design.
Neoplasms
Production, optimization, purification, characterization, and anti-cancer application of extracellular L-glutaminase produced from the marine bacterial isolate.
Neoplasms
Promiscuous Binding at the Crossroads of Numerous Cancer Pathways: Insight from the Binding of Glutaminase Interacting Protein with Glutaminase L.
Neoplasms
Properties and intracellular localization of Ehrlich ascites tumor cell glutaminase.
Neoplasms
Purification and characterization of l-glutaminase enzyme from camel liver: Enzymatic anticancer property.
Neoplasms
Purification, characterization, and anticancer and antioxidant activities of L-glutaminase from Aspergillus versicolor Faesay4.
Neoplasms
Q-ing tumor glutaminase for therapy.
Neoplasms
Recent Development of Small Molecule Glutaminase Inhibitors.
Neoplasms
Relative expression of mRNAS coding for glutaminase isoforms in CNS tissues and CNS tumors.
Neoplasms
Replication of the Shrimp Virus WSSV Depends on Glutamate-Driven Anaplerosis.
Neoplasms
Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.
Neoplasms
Rho GTPases and their roles in cancer metabolism.
Neoplasms
Selection of metastatic breast cancer cells based on adaptability of their metabolic state.
Neoplasms
Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.
Neoplasms
Selective reduction in glutaminase activity of l?Asparaginase by asparagine 248 to serine mutation: A combined computational and experimental effort in blood cancer treatment.
Neoplasms
Sensitisation of Ehrlich ascitic tumour cells to methotrexate by inhibiting glutaminase.
Neoplasms
Several Faces of Glutaminase Regulation in Cells.
Neoplasms
Short-term metabolic fate of L-[13N]glutamate in the Walker 256 carcinosarcoma in vivo.
Neoplasms
Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention.
Neoplasms
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.
Neoplasms
Small Angle X-Ray Scattering Studies of Mitochondrial Glutaminase C Reveal Extended Flexible Regions, and Link Oligomeric State with Enzyme Activity.
Neoplasms
Small molecule glutaminase inhibitors block glutamate release from stimulated microglia.
Neoplasms
Starving the Devourer: Cutting Cancer Off from Its Favorite Foods.
Neoplasms
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
Neoplasms
Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA).
Neoplasms
Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism.
Neoplasms
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
Neoplasms
Studies on the mechanism of inhibition of tumor growth by the enzyme glutaminase.
Neoplasms
Studies on two types of glutaminase in normal and tumour bearing mice.
Neoplasms
Submitochondrial localization and membrane topography of Ehrlich ascitic tumour cell glutaminase.
Neoplasms
SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells.
Neoplasms
Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.
Neoplasms
Targeted inhibition of glutaminase as a potential new approach for the treatment of
Neoplasms
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.
Neoplasms
Targeting cellular metabolism to improve cancer therapeutics.
Neoplasms
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.
Neoplasms
Targeting glutamine metabolism and autophagy: the combination for prostate cancer radiosensitization.
Neoplasms
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Neoplasms
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies.
Neoplasms
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.
Neoplasms
Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.
Neoplasms
Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential.
Neoplasms
The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.
Neoplasms
The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues.
Neoplasms
The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.
Neoplasms
The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
Neoplasms
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.
Neoplasms
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Neoplasms
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.
Neoplasms
The NF-?B member p65 controls glutamine metabolism through miR-23a.
Neoplasms
The origin and evolution of human glutaminases and their atypical C-terminal ankyrin repeats.
Neoplasms
The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme.
Neoplasms
The potential of halophilic and halotolerant bacteria for the production of antineoplastic enzymes: L-asparaginase and L-glutaminase.
Neoplasms
The proportionality of glutaminase content to growth rate and morphology of rat neoplasms.
Neoplasms
The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
Neoplasms
The role of glutaminase in cancer.
Neoplasms
The role of intestinal endotoxemia in a rat model of aluminum neurotoxicity.
Neoplasms
The SIRT1/HIF2? axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy.
Neoplasms
Therapeutic strategies impacting cancer cell glutamine metabolism.
Neoplasms
Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer.
Neoplasms
Therapeutic Targeting of Myc-Reprogrammed Cancer Cell Metabolism.
Neoplasms
Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.
Neoplasms
Tumor glutaminase purification.
Neoplasms
Tumor regulation of hepatic glutamine metabolism.
Neoplasms
TUMOUR-DERIVED GLUTAMATE: LINKING ABERRANT CANCER CELL METABOLISM TO PERIPHERAL SENSORY PAIN PATHWAYS.
Neoplasms
Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer.
Neoplasms
Upregulation of glutaminase 2 and neutrophil cytosolic factor 2 is associated with the poor prognosis of glioblastoma.
Neoplasms
Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer.
Neoplasms
[13N]Ammonia and L-[amide-13N]glutamine metabolism in glutaminase-sensitive and glutaminase-resistant murine tumors.
Neoplasms
[Concentration of free glutamine and glutaminase activity in the gastric mucosa of patients with precancerous diseases and cancer of the stomach]
Neoplasms
[Effect of L-glutaminase from Pseudomonas aureofaciens in experimental tumors]
Neoplasms
[Study of glutaminase and asparaginase activities in normal tissues and malignant tumors]
Neoplasms
[The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells]
Nephritis
[Glutaminase activity of rat kidney tissue in experimental nephritis]
Nephrosis
Glutaminase activity in the kidney of experimental nephrosis.
Neural Tube Defects
Altered Glutaminase 1 Activity During Neurulation and Its Potential Implications in Neural Tube Defects.
Neuroblastoma
Kinetics of a Novel Isoform of Phosphate Activated Glutaminase (PAG) in SH-SY5Y Neuroblastoma Cells.
Neuroblastoma
MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS).
Neuroblastoma
Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Neuroblastoma
Novel form of phosphate activated glutaminase in cultured astrocytes and human neuroblastoma cells, PAG in brain pathology and localization in the mitochondria.
Neurodegenerative Diseases
Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome.
Neurodegenerative Diseases
Glutaminase inhibitory activities of pentacyclic triterpenes isolated from Thymus vulgaris L.
Neurodegenerative Diseases
IL-1? and TNF-? induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase.
Neurodegenerative Diseases
Potentiation of Excitotoxicity in HIV-1 Associated Dementia and the Significance of Glutaminase.
Neurodegenerative Diseases
Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with sporadic amyotrophic lateral sclerosis--a study of potential pathogenetic mechanisms in neurodegenerative diseases.
Neuroinflammatory Diseases
?1-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells.
Neuroinflammatory Diseases
Extracellular Vesicles from Hyperammonemic Rats Induce Neuroinflammation and Motor Incoordination in Control Rats.
Neuroinflammatory Diseases
Glutaminase 1 Regulates Neuroinflammation After Cerebral Ischemia Through Enhancing Microglial Activation and Pro-Inflammatory Exosome Release.
Neuroinflammatory Diseases
Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate.
Neuroinflammatory Diseases
Glutaminase C overexpression in the brain induces learning deficits, synaptic dysfunctions, and neuroinflammation in mice.
Neuroinflammatory Diseases
Glutaminase in microglia: A novel regulator of neuroinflammation.
Neuroinflammatory Diseases
Glutaminase-containing microvesicles from HIV-1-infected macrophages and immune-activated microglia induce neurotoxicity.
Neuroinflammatory Diseases
Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.
Neuroinflammatory Diseases
TNF-? promotes extracellular vesicle release in mouse astrocytes through glutaminase.
Osteoporosis
MicroRNA-200a-3p accelerates the progression of osteoporosis by targeting glutaminase to inhibit osteogenic differentiation of bone marrow mesenchymal stem cells.
Osteosarcoma
Acetone immersion enhanced MALDI-MS imaging of small molecule metabolites in biological tissues.
Osteosarcoma
Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma.
Osteosarcoma
Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression.
Osteosarcoma
[13N]Ammonia and L-[amide-13N]glutamine metabolism in glutaminase-sensitive and glutaminase-resistant murine tumors.
Ovarian Neoplasms
Acivicin with glutaminase regulates proliferation and invasion of human MCF-7 and OAW-42 cells--an in vitro study.
Ovarian Neoplasms
Altered glutamine metabolism in platinum resistant ovarian cancer.
Ovarian Neoplasms
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ovarian Neoplasms
Effect of purified glutaminase from human ascites fluid on experimental tumor bearing mice.
Ovarian Neoplasms
Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.
Ovarian Neoplasms
Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.
Ovarian Neoplasms
Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant cancers.
Ovarian Neoplasms
Localization of phosphate dependent glutaminase in ascites fluid of ovarian cancer patient.
Ovarian Neoplasms
Modulation of tumor induced angiogenesis in Ehrlich ascites tumor.
Ovarian Neoplasms
Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Pancreatic Neoplasms
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Pancreatic Neoplasms
Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.
Pancreatic Neoplasms
Nutrient stress-dysregulated antisense lncRNA GLS-AS impairs GLS-mediated metabolism and represses pancreatic cancer progression.
Pancreatic Neoplasms
TFEB Supports Pancreatic Cancer Growth through the Transcriptional Regulation of Glutaminase.
Pancreatic Neoplasms
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
Pancreatic Neoplasms
Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer.
Pancreatitis
L: -Asparaginase as Potent Anti-leukemic Agent and Its Significance of Having Reduced Glutaminase Side Activity for Better treatment of Acute Lymphoblastic Leukaemia.
Pick Disease of the Brain
Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.
Polycystic Kidney Diseases
Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Polycythemia Vera
[L-asparaginase and L-glutaminase activities in leukocytes and plasma in polycythemia vera]
Potassium Deficiency
Relationship of phosphate-dependent glutaminase activity to ammonia excretion in potassium deficiency and acidosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enhanced catalysis of l-asparaginase from Bacillus licheniformis by a rational redesign.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isolation and identification of actinomycetes for production of novel extracellular glutaminase free L-asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
L-glutaminase and L-asparaginase by extracorporeal route in acute lymphoblastic leukemia therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Low glutamine concentrations induce phenotypical and functional differentiation of U937 myelomonocytic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Purification and Characterization of Asparaginase from Phaseolus vulgaris Seeds.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Purification and characterization of glutaminase free asparaginase from Pseudomonas otitidis: Induce apoptosis in human leukemia MOLT-4 cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The potential of halophilic and halotolerant bacteria for the production of antineoplastic enzymes: L-asparaginase and L-glutaminase.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia.
Prostatic Neoplasms
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.
Prostatic Neoplasms
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.
Prostatic Neoplasms
c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer.
Prostatic Neoplasms
Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer.
Prostatic Neoplasms
Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters.
Prostatic Neoplasms
NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
Prostatic Neoplasms
Targeting glutamine metabolism and autophagy: the combination for prostate cancer radiosensitization.
Psoriasis
GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis.
Pulmonary Fibrosis
Inhibition of Glutaminase 1 Attenuates Experimental Pulmonary Fibrosis.
Pulmonary Fibrosis
SIRT7-mediated modulation of glutaminase 1 regulates TGF-?-induced pulmonary fibrosis.
Pyelonephritis
[Renal glutaminase I activities in experimental and human chronic pyelonephritis (author's transl)]
Renal Insufficiency
Glutaminase activity of the kidney in experimental renal failure of rats.
Renal Insufficiency, Chronic
[Activity of glutamine deaminating enzymes in the kidneys, liver and serum of dogs with renal failure and under normal conditions]
Reperfusion Injury
Mitochondrial Metabolism behind Region-Specific Resistance to Ischemia-Reperfusion Injury in Gerbil Hippocampus. Role of PKC?II and Phosphate-Activated Glutaminase.
Reperfusion Injury
The effects of administration of nitric oxide inhibitors during small bowel preservation and reperfusion.
Respiratory Insufficiency
Identification of a Loss-of-Function Mutation in the Context of Glutaminase Deficiency and Neonatal Epileptic Encephalopathy.
Rett Syndrome
Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome.
Sarcoma, Myeloid
Prominent glutamine oxidation activity in mitochondria of hematopoietic tumors.
Seizures
Acute and long-term effects of chlorpromazine on glutamine synthetase and glutaminase in rat brain.
Seizures
Functional significance of the activities of glutaminase and ornithine-?-aminotransferase in rat brain.
Seizures
Identification of a Loss-of-Function Mutation in the Context of Glutaminase Deficiency and Neonatal Epileptic Encephalopathy.
Seizures
Pentylenetetrazol-induced seizures in adult rats are associated with plastic changes to the dendritic spines on hippocampal CA1 pyramidal neurons.
Seizures
Studies on sound-induced epilepsy in mice.
Seizures
[Metabolic studies on epileptic seizures. The activity of glutaminase and glutamine synthetase and ammonia metabolism before and during cerebral convulsions]
Sepsis
Berberine attenuates lipopolysaccharide-induced impairments of intestinal glutamine transport and glutaminase activity in rat.
Sepsis
Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure.
Sepsis
Increased glutamine consumption in small intestine epithelial cells during sepsis in rats.
Sepsis
[Influence of recombinant growth hormone on protein metabolism during severe infection: an animal experiment]
Squamous Cell Carcinoma of Head and Neck
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Starvation
Distribution of phosphate-activated glutaminase isozymes in the chicken: absence from liver but presence of high activity in pectoralis muscle.
Starvation
Drug-induced amino acid deprivation as strategy for cancer therapy.
Starvation
Effect of starvation or streptozotocin-diabetes on phosphate-activated glutaminase of different rat brain regions.
Starvation
Effects of starvation on the maximal activities of some glycolytic and citric acid-cycle enzymes and glutaminase in mucosa of the small intestine of the rat.
Starvation
Fuel utilization in colonocytes of the rat.
Starvation
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Starvation
Glutamine deficiency promotes stemness and chemoresistance in tumor cells through DRP1-induced mitochondrial fragmentation.
Starvation
Hepatic glutaminase expression: relationship to kidney-type glutaminase and to the urea cycle.
Starvation
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Starvation
Isolation and screening of extracellular anticancer enzymes from halophilic and halotolerant bacteria from different saline environments in Iran.
Starvation
LncRNA GIRGL drives CAPRIN1-mediated phase separation to suppress glutaminase-1 translation under glutamine deprivation.
Starvation
Regulation of glutaminase activity and glutamine metabolism.
Starvation
Starvation alters the activity and mRNA level of glutaminase and glutamine synthetase in the rat intestine.
Starvation
Targeting glutamine metabolism slows soft tissue sarcoma growth.
Starvation
Transcriptional control of rat hepatic glutaminase expression by dietary protein level and starvation.
Starvation
[Features of the interconversion of alpha-ketoglutarate--glutamate in brain mitochondria of exothermic animals during hibernation]
Stomach Neoplasms
iTRAQ-Based Quantitative Proteomics Approach Identifies Novel Diagnostic Biomarkers That Were Essential for Glutamine Metabolism and Redox Homeostasis for Gastric Cancer.
Stomach Neoplasms
Pyruvate kinase isozyme M2 and glutaminase might be promising molecular targets for the treatment of gastric cancer.
Stomach Neoplasms
[Concentration of free glutamine and glutaminase activity in the gastric mucosa of patients with precancerous diseases and cancer of the stomach]
Thrombosis
L: -Asparaginase as Potent Anti-leukemic Agent and Its Significance of Having Reduced Glutaminase Side Activity for Better treatment of Acute Lymphoblastic Leukaemia.
Thyroid Cancer, Papillary
Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer.
Triple Negative Breast Neoplasms
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
Triple Negative Breast Neoplasms
Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
Triple Negative Breast Neoplasms
Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Triple Negative Breast Neoplasms
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Tuberculosis
Regulation of active site coupling in glutamine-dependent NAD(+) synthetase.
Tuberculosis
[Glutaminase activity and intensity of glutamine metabolism in the lungs and lymph nodes in tuberculosis]
Tuberculosis, Pulmonary
[Activity of blood glutaminase in patients with pulmonary tuberculosis and other diseases]
Uremia
[Amylase metabolism and changes in glutaminase and glutamate-synthetase activity in brain during experimental uremia]
Urinary Bladder Neoplasms
LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase expression.
Urinary Bladder Neoplasms
miR-1-3p Contributes to Cell Proliferation and Invasion by Targeting Glutaminase in Bladder Cancer Cells.
Uterine Cervical Neoplasms
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Uterine Cervical Neoplasms
Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation.
Vitamin E Deficiency
[GLUTAMINASE ACTIVITY OF THE SKELETAL MUSCLE CELLS UNDER NORMAL CONDITIONS AND IN VITAMIN E DEFICIENCY.]
Xeroderma Pigmentosum
Physical and genetic linkage of glutaminase (Gls), signal transducer and activator of transcription 1 (Stat1), and xeroderma pigmentosum complementation group G (Xpg) on mouse proximal chromosome 1.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.1
5,5'-(sulfanediyldiethane-2,1-diyl)bis(1,3,4-thiadiazol-2-amine)
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0014
5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]-N-[2-(4-phenylpiperidin-1-yl)ethyl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.01
5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]-N-[2-(piperidin-1-yl)ethyl]pentanamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0046
5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.1
5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]-N-[4-(trifluoromethyl)benzyl]pentanamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.00006 - 0.1
bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide
0.0033
N,N'-[sulfanediylbis(ethane-2,1-diyl-1,3,4-thiadiazole-5,2-diyl)]bis(2-phenylacetamide)
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.1
N-(2-aminoethyl)-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0027
N-(5-[2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl]-[1,3,4]thiadiazol-2-yl)-2-phenyl-acetamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.1
N-benzyl-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.1
N-methyl-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]pentanamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.011
N-tert-butyl-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0052
N-tert-butyl-N-methyl-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0081
N-[2-(1-methylpyrrolidin-2-yl)ethyl]-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0038
N-[2-(4-hydroxypiperidin-1-yl)ethyl]-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.026
N-[2-(diethylamino)ethyl]-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.048
N-[4-(dimethylamino)benzyl]-5-[5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]pentanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.1
N-[4-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3-thiazol-2-yl]-2-phenylacetamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.061
N-[5-(2-[[2-(5-amino-1,3,4-thiadiazol-2-yl)ethyl]sulfinyl]ethyl)-1,3,4-thiadiazol-2-yl]-2-phenylacetamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.015
N-[5-[2-(5-amino-1,3,4-thiadiazol-2-yl)ethyl]-1,3,4-thiadiazol-2-yl]-2-phenylacetamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0026
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-2-(4-fluorophenyl)acetamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0045
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-2-(4-methylphenyl)acetamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.022
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-2-cyclohexylacetamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0019
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-2-phenylacetamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.012
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-2-phenylpropanamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.1
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-3-phenylpropanamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0072
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]benzamide
Homo sapiens
in 45 mM phosphate buffer (pH 8.2), at 22°C
0.1
N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3-thiazol-2-yl]-2-phenylacetamide
Homo sapiens
IC50 above 0.1 mM, in 45 mM phosphate buffer (pH 8.2), at 22°C
0.0231 - 0.05
(2R)-1-(2-formyl-3,6-dihydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
0.0251 - 0.05
(2R)-1-(2-hydroxy-5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)pentadecan-2-yl acetate
0.05 - 0.5
(2R)-1-(2-hydroxy-5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
0.00026 - 0.0029
(2R)-1-(3,6-dihydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
0.00028 - 0.0021
(2R)-1-(5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)pentadecan-2-yl acetate
0.00029 - 0.0039
(2R)-1-(5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
0.0057 - 0.069
(2R)-1-[3-(acetyloxy)-6-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl]pentadecan-2-yl acetate
0.0317 - 0.05
(2R)-1-[3-(acetyloxy)-6-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl]tridecan-2-yl acetate
0.05 - 0.0527
(2S)-1-(5-methoxycyclohexa-1,4-dien-1-yl)heptan-2-ol
0.05 - 0.5
2-hydroxy-5-methoxy-3-tridecylcyclohexa-2,5-diene-1,4-dione
0.05 - 0.5
2-methoxy-6-pentadecylcyclohexa-2,5-diene-1,4-dione
0.0325 - 0.5
2-methoxy-6-tridecylcyclohexa-2,5-diene-1,4-dione
0.0027 - 0.0769
2-methyl-5-[(7Z)-pentadec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
0.05 - 0.0598
2-methyl-5-[(7Z)-tridec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
0.0076 - 0.0524
3-[(2S)-2-hydroxypentadecyl]-5-methoxycyclohexa-2,5-dien-1-ol
0.0047 - 0.041
4-hydroxy-2-methoxy-6-(2-oxopentadecyl)cyclohexa-2,5-dien-1-yl acetate
0.0031 - 0.0139
5-[(6Z)-13-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]-2-methylbenzene-1,3-diol
0.0021 - 0.0117
5-[(6Z)-13-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]benzene-1,3-diol
0.0029 - 0.0096
5-[(6Z)-13-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]benzene-1,3-diol
0.0025 - 0.0367
5-[(7Z)-13-(3-hydroxy-5-methoxyphenyl)tridec-7-en-1-yl]-2-methylcyclohexa-1,4-diene-1,3-diol
0.0023 - 0.07
5-[(7Z)-15-(3-hydroxy-5-methoxyphenyl)pentadec-7-en-1-yl]-2-methylcyclohexa-1,4-diene-1,3-diol
0.0029 - 0.073
5-[(7Z)-pentadec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
0.0028 - 0.0765
5-[(7Z)-tridec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
0.0029 - 0.0175
5-[(8Z)-15-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]-2-methylbenzene-1,3-diol
0.0023 - 0.0119
5-[(8Z)-15-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]benzene-1,3-diol
0.0029 - 0.0134
5-[(8Z)-15-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]benzene-1,3-diol
0.0028 - 0.0144
5-[14-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tetradecyl]benzene-1,3-diol
0.0599
6-diazo-5-oxo-L-norleucine
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.088
bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide
Homo sapiens
pH 8.5, temperature not specified in the publication, isozyme GLS2
0.00008 - 0.0636
bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl) ethyl sulfide
0.00006
bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide
Homo sapiens
pH 8.5, temperature not specified in the publication, isozyme GLS1
0.00008
bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide
Homo sapiens
pH 8.5, temperature not specified in the publication, wild-type GAC
0.1
bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide
Homo sapiens
pH 8.5, temperature not specified in the publication, GAC mutant F322S/F318Y and GAC mutant Y394L
0.0231
(2R)-1-(2-formyl-3,6-dihydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.05
(2R)-1-(2-formyl-3,6-dihydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0251
(2R)-1-(2-hydroxy-5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)pentadecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.05
(2R)-1-(2-hydroxy-5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)pentadecan-2-yl acetate
Homo sapiens
-
IC50 above 0.05 mM, isoform KGA, at pH 8.6 and 37°C
0.05
(2R)-1-(2-hydroxy-5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.5
(2R)-1-(2-hydroxy-5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
IC50 above 0.05 mM, isoform KGA, at pH 8.6 and 37°C
0.00026
(2R)-1-(3,6-dihydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0029
(2R)-1-(3,6-dihydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.00028
(2R)-1-(5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)pentadecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0021
(2R)-1-(5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)pentadecan-2-yl acetate
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.00029
(2R)-1-(5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0039
(2R)-1-(5-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)tridecan-2-yl acetate
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0057
(2R)-1-[3-(acetyloxy)-6-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl]pentadecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.069
(2R)-1-[3-(acetyloxy)-6-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl]pentadecan-2-yl acetate
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0317
(2R)-1-[3-(acetyloxy)-6-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl]tridecan-2-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.05
(2R)-1-[3-(acetyloxy)-6-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl]tridecan-2-yl acetate
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.05
(2S)-1-(5-methoxycyclohexa-1,4-dien-1-yl)heptan-2-ol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0527
(2S)-1-(5-methoxycyclohexa-1,4-dien-1-yl)heptan-2-ol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.05
2-hydroxy-5-methoxy-3-tridecylcyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.5
2-hydroxy-5-methoxy-3-tridecylcyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
IC50 above 0.05 mM, isoform KGA, at pH 8.6 and 37°C
0.05
2-methoxy-6-pentadecylcyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.5
2-methoxy-6-pentadecylcyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
IC50 above 0.05 mM, isoform KGA, at pH 8.6 and 37°C
0.0325
2-methoxy-6-tridecylcyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.5
2-methoxy-6-tridecylcyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
IC50 above 0.05 mM, isoform KGA, at pH 8.6 and 37°C
0.0027
2-methyl-5-[(7Z)-pentadec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0769
2-methyl-5-[(7Z)-pentadec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.05
2-methyl-5-[(7Z)-tridec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0598
2-methyl-5-[(7Z)-tridec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0076
3-[(2S)-2-hydroxypentadecyl]-5-methoxycyclohexa-2,5-dien-1-ol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0524
3-[(2S)-2-hydroxypentadecyl]-5-methoxycyclohexa-2,5-dien-1-ol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0047
4-hydroxy-2-methoxy-6-(2-oxopentadecyl)cyclohexa-2,5-dien-1-yl acetate
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.041
4-hydroxy-2-methoxy-6-(2-oxopentadecyl)cyclohexa-2,5-dien-1-yl acetate
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0031
5-[(6Z)-13-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]-2-methylbenzene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0139
5-[(6Z)-13-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]-2-methylbenzene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0021
5-[(6Z)-13-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0117
5-[(6Z)-13-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0029
5-[(6Z)-13-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0096
5-[(6Z)-13-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tridec-6-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0025
5-[(7Z)-13-(3-hydroxy-5-methoxyphenyl)tridec-7-en-1-yl]-2-methylcyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0367
5-[(7Z)-13-(3-hydroxy-5-methoxyphenyl)tridec-7-en-1-yl]-2-methylcyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0023
5-[(7Z)-15-(3-hydroxy-5-methoxyphenyl)pentadec-7-en-1-yl]-2-methylcyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.07
5-[(7Z)-15-(3-hydroxy-5-methoxyphenyl)pentadec-7-en-1-yl]-2-methylcyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0029
5-[(7Z)-pentadec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.073
5-[(7Z)-pentadec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0028
5-[(7Z)-tridec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0765
5-[(7Z)-tridec-7-en-1-yl]cyclohexa-1,4-diene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0029
5-[(8Z)-15-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]-2-methylbenzene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0175
5-[(8Z)-15-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]-2-methylbenzene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0023
5-[(8Z)-15-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0119
5-[(8Z)-15-(3,5-dihydroxy-4-methylcyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0029
5-[(8Z)-15-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0134
5-[(8Z)-15-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)pentadec-8-en-1-yl]benzene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0028
5-[14-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tetradecyl]benzene-1,3-diol
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
0.0144
5-[14-(3-hydroxy-5-methoxycyclohexa-1,4-dien-1-yl)tetradecyl]benzene-1,3-diol
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.00008
bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl) ethyl sulfide
Homo sapiens
-
isoform KGA, at pH 8.6 and 37°C
0.0636
bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl) ethyl sulfide
Homo sapiens
-
isoform GAB, at pH 8.6 and 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.5.1.2 glutaminase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
